<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Nucleos(t)ide-based multi-target drugs in the treatment of HBV and HIV infections.</p>
 </caption>
 <alt-text id="alttext0050">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Nucleos(t)ide-type drugs with multi-target activity</th>
    <th>Approved anti-HBV monotherapy</th>
    <th>Approved combination drug for HIV</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Tenofovir disoproxil fumarate (TDF)</td>
    <td align="left">Viread, Gilead, 2008</td>
    <td align="left">Viread, Gilead Sciences, 2001 (tenofovir disoproxil fumarate)
     <break/>Truvada, Gilead Sciences, 2004 (emtricitabine + tenofovir disoproxil fumarate)
     <break/>Atripla, Gilead Sciences, Bristol-Myers Squibb, 2006 (emtricitabine + efavirenz + tenofovir disoproxil fumarate)
     <break/>Complera, Gilead Sciences, 2011 (emtricitabine + rilpivirine + tenofovir disoproxil fumarate)
     <break/>Stribild, Gilead Sciences, 2012 (elvitegravir + cobicistat + emtricitabine + tenofovir disoproxil fumarate)
     <break/>Delstrigo, Merck, 2018 (doravirine + lamivudine +tenofovir disoproxil fumarate)
     <break/>Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine + tenofovir disoproxil fumarate)
     <break/>Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine + tenofovir disoproxil fumarate)
    </td>
   </tr>
   <tr>
    <td align="left">Tenofovir alafenamide fumarate (TAF)</td>
    <td align="left">Vemlidy, Gilead, 2016</td>
    <td align="left">Genvoya, Gilead Sciences 2015 (elvitegravir + cobicistat + emtricitabine, + tenofovir alafenamide)
     <break/>Descovy, Gilead Sciences, 2016 (emtricitabine + tenofovir alafenamide)
     <break/>Odefsey, Gilead Sciences, 2016 (emtricitabine + rilpivirine + tenofovir alafenamide)
     <break/>Symtuza, Janssen Therapeutics, 2018 (darunavir + cobicistat + emtricitabine + tenofovir alafenamide)
     <break/>Biktarvy, Gilead Sciences, 2018 (bictegravir + emtricitabine + tenofovir alafenamide)
    </td>
   </tr>
   <tr>
    <td align="left">Lamivudine (3TC)</td>
    <td align="left">Epivir, Glaxo Wellcome, 1998</td>
    <td align="left">Combivir, ViiV Healthcare, 2000 (lamivudine + zidovudine)
     <break/>Trizivir, ViiV Healthcare, 2000 (abacavir + lamivudine + zidovudine)
     <break/>Epzicom, ViiV Healthcare, 2004 (abacavir + lamivudine)
     <break/>Triumeq, ViiV HealthCare, 2014 (abacavir + dolutegravir + lamivudine)
     <break/>Dutrebis, Merck, 2015 (lamivudine + raltegravir)
     <break/>Delstrigo, Merck, 2018 (doravirine + lamivudine +tenofovir disoproxil fumarate)
     <break/>Cimduo, Mylan Pharmaceuticals, 2018 (lamivudine + tenofovir disoproxil fumarate)
     <break/>Symfi Lo, Mylan Pharmaceuticals, 2018 (efavirenz + lamivudine + tenofovir disoproxil fumarate)
     <break/>Dovato, ViiV Healthcare, 2019 (dolutegravir + lamivudine)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
